Selected research
Market Structure
Global Biosimilar Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Biosimilar market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Biosimilar include Qilu Pharmaceutical, Bio-Thera, Zhejiang Hisun, Shanghai Henlius, Innovent Biologics, Jiangsu Hengrui, Gan&Lee, Tonghua Dongbao and United Laboratory, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Biosimilar market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Biosimilar and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Biosimilar revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Biosimilar market size, projected growth trends, production technologies, key applications, and end-use industries.
Biosimilar Segment by Company
Qilu Pharmaceutical
Bio-Thera
Zhejiang Hisun
Shanghai Henlius
Innovent Biologics
Jiangsu Hengrui
Gan&Lee
Tonghua Dongbao
United Laboratory
3SBIO
Luye Pharma
Biosimilar Segment by Type
Biosimilar Monoclonal Antibodies
Biosimilar Insulin
Others
Biosimilar Segment by Application
Cancer
Immunological Diseases
Diabetes
Others
Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Biosimilar in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar industry.
Chapter 3: Detailed analysis of Biosimilar companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilarrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biosimilar Monoclonal Antibodies
- Biosimilar Insulin
- Others
Applications
- Cancer
- Immunological Diseases
- Diabetes
- Others
Companies covered
- Qilu Pharmaceutical
- Bio-Thera
- Zhejiang Hisun
- Shanghai Henlius
- Innovent Biologics
- Jiangsu Hengrui
- Gan&Lee
- Tonghua Dongbao
- United Laboratory
- 3SBIO
- Luye Pharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Biosimilar Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Biosimilar Monoclonal Antibodies
- 1.2.3 Biosimilar Insulin
- 1.2.4 Others
- 1.3 Market Analysis by Application
- 1.3.1 Global Biosimilar Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Cancer
- 1.3.3 Immunological Diseases
- 1.3.4 Diabetes
- 1.3.5 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Biosimilar Growth Trends by Region
- 1.5.1 Global Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Biosimilar Market Size by Region (2021-2026)
- 1.5.3 Biosimilar Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Biosimilar Market Dynamics
- 2.1 Biosimilar Industry Trends
- 2.2 Biosimilar Industry Drivers
- 2.3 Biosimilar Industry Opportunities and Challenges
- 2.4 Biosimilar Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Biosimilar Revenue by Company (2021-2026)
- 3.2 Global Biosimilar Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Biosimilar Key Company Head office and Area Served
- 3.4 Global Biosimilar Company, Product Type & Application
- 3.5 Global Biosimilar Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Biosimilar Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Biosimilar Players Market Share by Revenue in 2025
- 3.6.3 2025 Biosimilar Tier 1, Tier 2, and Tier 3
4 Biosimilar Market by Type
- 4.1 Global Biosimilar Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Biosimilar Market Size by Type (2021-2032)
- 4.3 Global Biosimilar Market Size Share by Type (2021-2032)
5 Biosimilar Market by Application
- 5.1 Global Biosimilar Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Biosimilar Market Size by Application (2021-2032)
- 5.3 Global Biosimilar Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Qilu Pharmaceutical
- 6.1.1 Qilu Pharmaceutical Company Information
- 6.1.2 Qilu Pharmaceutical Business Overview
- 6.1.3 Qilu Pharmaceutical Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Qilu Pharmaceutical Biosimilar Product Portfolio
- 6.1.5 Qilu Pharmaceutical Recent Developments
- 6.2 Bio-Thera
- 6.2.1 Bio-Thera Company Information
- 6.2.2 Bio-Thera Business Overview
- 6.2.3 Bio-Thera Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Bio-Thera Biosimilar Product Portfolio
- 6.2.5 Bio-Thera Recent Developments
- 6.3 Zhejiang Hisun
- 6.3.1 Zhejiang Hisun Company Information
- 6.3.2 Zhejiang Hisun Business Overview
- 6.3.3 Zhejiang Hisun Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Zhejiang Hisun Biosimilar Product Portfolio
- 6.3.5 Zhejiang Hisun Recent Developments
- 6.4 Shanghai Henlius
- 6.4.1 Shanghai Henlius Company Information
- 6.4.2 Shanghai Henlius Business Overview
- 6.4.3 Shanghai Henlius Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Shanghai Henlius Biosimilar Product Portfolio
- 6.4.5 Shanghai Henlius Recent Developments
- 6.5 Innovent Biologics
- 6.5.1 Innovent Biologics Company Information
- 6.5.2 Innovent Biologics Business Overview
- 6.5.3 Innovent Biologics Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Innovent Biologics Biosimilar Product Portfolio
- 6.5.5 Innovent Biologics Recent Developments
- 6.6 Jiangsu Hengrui
- 6.6.1 Jiangsu Hengrui Company Information
- 6.6.2 Jiangsu Hengrui Business Overview
- 6.6.3 Jiangsu Hengrui Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Jiangsu Hengrui Biosimilar Product Portfolio
- 6.6.5 Jiangsu Hengrui Recent Developments
- 6.7 Gan&Lee
- 6.7.1 Gan&Lee Company Information
- 6.7.2 Gan&Lee Business Overview
- 6.7.3 Gan&Lee Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Gan&Lee Biosimilar Product Portfolio
- 6.7.5 Gan&Lee Recent Developments
- 6.8 Tonghua Dongbao
- 6.8.1 Tonghua Dongbao Company Information
- 6.8.2 Tonghua Dongbao Business Overview
- 6.8.3 Tonghua Dongbao Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Tonghua Dongbao Biosimilar Product Portfolio
- 6.8.5 Tonghua Dongbao Recent Developments
- 6.9 United Laboratory
- 6.9.1 United Laboratory Company Information
- 6.9.2 United Laboratory Business Overview
- 6.9.3 United Laboratory Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 United Laboratory Biosimilar Product Portfolio
- 6.9.5 United Laboratory Recent Developments
- 6.10 3SBIO
- 6.10.1 3SBIO Company Information
- 6.10.2 3SBIO Business Overview
- 6.10.3 3SBIO Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 3SBIO Biosimilar Product Portfolio
- 6.10.5 3SBIO Recent Developments
- 6.11 Luye Pharma
- 6.11.1 Luye Pharma Company Information
- 6.11.2 Luye Pharma Business Overview
- 6.11.3 Luye Pharma Biosimilar Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Luye Pharma Biosimilar Product Portfolio
- 6.11.5 Luye Pharma Recent Developments
7 North America
- 7.1 North America Biosimilar Market Size (2021-2032)
- 7.2 North America Biosimilar Market Size by Type
- 7.2.1 North America Biosimilar Market Size by Type (2021-2026)
- 7.2.2 North America Biosimilar Market Size by Type (2027-2032)
- 7.2.3 North America Biosimilar Market Share by Type (2021-2032)
- 7.3 North America Biosimilar Market Size by Application
- 7.3.1 North America Biosimilar Market Size by Application (2021-2026)
- 7.3.2 North America Biosimilar Market Size by Application (2027-2032)
- 7.3.3 North America Biosimilar Market Share by Application (2021-2032)
- 7.4 North America Biosimilar Market Size by Country
- 7.4.1 North America Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Biosimilar Market Size by Country (2021-2026)
- 7.4.3 North America Biosimilar Market Size by Country (2027-2032)
- 7.4.4 North America Biosimilar Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Biosimilar Market Size (2021-2032)
- 8.2 Europe Biosimilar Market Size by Type
- 8.2.1 Europe Biosimilar Market Size by Type (2021-2026)
- 8.2.2 Europe Biosimilar Market Size by Type (2027-2032)
- 8.2.3 Europe Biosimilar Market Share by Type (2021-2032)
- 8.3 Europe Biosimilar Market Size by Application
- 8.3.1 Europe Biosimilar Market Size by Application (2021-2026)
- 8.3.2 Europe Biosimilar Market Size by Application (2027-2032)
- 8.3.3 Europe Biosimilar Market Share by Application (2021-2032)
- 8.4 Europe Biosimilar Market Size by Country
- 8.4.1 Europe Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Biosimilar Market Size by Country (2021-2026)
- 8.4.3 Europe Biosimilar Market Size by Country (2027-2032)
- 8.4.4 Europe Biosimilar Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Biosimilar Market Size (2021-2032)
- 9.2 China Biosimilar Market Size by Type
- 9.2.1 China Biosimilar Market Size by Type (2021-2026)
- 9.2.2 China Biosimilar Market Size by Type (2027-2032)
- 9.2.3 China Biosimilar Market Share by Type (2021-2032)
- 9.3 China Biosimilar Market Size by Application
- 9.3.1 China Biosimilar Market Size by Application (2021-2026)
- 9.3.2 China Biosimilar Market Size by Application (2027-2032)
- 9.3.3 China Biosimilar Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Biosimilar Market Size (2021-2032)
- 10.2 Asia Biosimilar Market Size by Type
- 10.2.1 Asia Biosimilar Market Size by Type (2021-2026)
- 10.2.2 Asia Biosimilar Market Size by Type (2027-2032)
- 10.2.3 Asia Biosimilar Market Share by Type (2021-2032)
- 10.3 Asia Biosimilar Market Size by Application
- 10.3.1 Asia Biosimilar Market Size by Application (2021-2026)
- 10.3.2 Asia Biosimilar Market Size by Application (2027-2032)
- 10.3.3 Asia Biosimilar Market Share by Application (2021-2032)
- 10.4 Asia Biosimilar Market Size by Country
- 10.4.1 Asia Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Biosimilar Market Size by Country (2021-2026)
- 10.4.3 Asia Biosimilar Market Size by Country (2027-2032)
- 10.4.4 Asia Biosimilar Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Biosimilar Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Biosimilar Market Size by Type
- 11.2.1 South America, Middle East & Africa Biosimilar Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Biosimilar Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Biosimilar Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Biosimilar Market Size by Application
- 11.3.1 South America, Middle East & Africa Biosimilar Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Biosimilar Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Biosimilar Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Biosimilar Market Size by Country
- 11.4.1 South America, Middle East & Africa Biosimilar Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Biosimilar Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Biosimilar Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Biosimilar Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst